Sign Out
In cases of known hypersensitivity to one of its ingredients, to ephedrine or any of the piperazine; in patients receiving dihydroergotamine (see Interactions); during treatment with MAOI and also for 2 weeks after their discontinuation (see Interactions); in case of severe hypertension or severe coronary artery disease; in cases of renal insufficiency, uncontrolled hyperthyroidism, severe arrhythmias, pheochromocytoma, narrow-angle glaucoma or urinary retention; in patients with a history of stroke; or in patients at high risk of developing haemorrhagic stroke; 3rd trimester of pregnancy (see Use in Pregnancy & Lactation).
Zyrtec-D is not recommended in children under 12 years of age.
